ATE260096T1 - Agglomerate durch kristallisation - Google Patents

Agglomerate durch kristallisation

Info

Publication number
ATE260096T1
ATE260096T1 AT00917035T AT00917035T ATE260096T1 AT E260096 T1 ATE260096 T1 AT E260096T1 AT 00917035 T AT00917035 T AT 00917035T AT 00917035 T AT00917035 T AT 00917035T AT E260096 T1 ATE260096 T1 AT E260096T1
Authority
AT
Austria
Prior art keywords
agglomerates
crystalization
lactum
solvents
suspension
Prior art date
Application number
AT00917035T
Other languages
English (en)
Inventor
Johannes Booij
Ageeth Geertruida Lefferts
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE260096(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Application granted granted Critical
Publication of ATE260096T1 publication Critical patent/ATE260096T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT00917035T 1999-04-01 2000-04-03 Agglomerate durch kristallisation ATE260096T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201034 1999-04-01
PCT/EP2000/002917 WO2000041478A2 (en) 1999-04-01 2000-04-03 Agglomerates by crystallisation

Publications (1)

Publication Number Publication Date
ATE260096T1 true ATE260096T1 (de) 2004-03-15

Family

ID=8240058

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00917035T ATE260096T1 (de) 1999-04-01 2000-04-03 Agglomerate durch kristallisation

Country Status (12)

Country Link
US (3) US6979735B1 (de)
EP (1) EP1165049B2 (de)
CN (1) CN1209099C (de)
AT (1) ATE260096T1 (de)
AU (1) AU3817300A (de)
CA (1) CA2364342C (de)
DE (1) DE60008508T9 (de)
ES (1) ES2215628T5 (de)
MX (1) MXPA01009808A (de)
SI (1) SI1165049T2 (de)
TR (1) TR200102771T2 (de)
WO (1) WO2000041478A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
CA2424462C (en) * 2000-10-20 2010-03-30 Biochemie Gesellschaft M.B.H. Clavulanic acid pharmaceutical compositions
GB0031267D0 (en) * 2000-12-21 2001-01-31 Smithkline Beecham Plc Novel compositions
US20040132712A1 (en) * 2001-04-12 2004-07-08 Otto Damon Pharmaceutical compositions comprising clavulanic acid
AT500131A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Organische verbindungen
AT500132A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Organische verbindungen
AT500134A1 (de) * 2002-02-01 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
AT500133A1 (de) * 2002-02-06 2005-11-15 Sandoz Ag Verfahren zur herstellung eines entmischungsstabilen granulats
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
CN102260278B (zh) * 2003-03-21 2015-05-06 中化帝斯曼制药有限公司荷兰公司 三水羟氨苄青霉素结晶粉末
EA012296B1 (ru) * 2004-01-06 2009-08-28 Панацея Биотек Лтд. Фармацевтическая композиция с контролируемым высвобождением, содержащая не растворимый в кислотах полимер и биоадгезивный полимер
EP3240563B1 (de) 2014-12-29 2020-12-09 Bioventus LLC Systeme und verfahren zur verbesserten freisetzung von osteoinduktiven moleküle zur knochenreparatur
CN108905264A (zh) * 2018-07-17 2018-11-30 凯莱英医药集团（天津）股份有限公司 连续化结晶方法在β-内酰胺类抗生素合成中的应用及连续化结晶系统
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697506A (en) * 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3692781A (en) * 1971-02-26 1972-09-19 Glaxo Lab Ltd Recovery of pure cephalexin from acidic reaction mixtures
US4138555A (en) * 1971-05-14 1979-02-06 Glaxo Laboratories, Limited (6R,7R)-7-[2-aryl-2-(etherified oximino)acetamido]-3-carbamoyloxymethylceph-3-em-4-carboxylic acid 1-oxides
AR206201A1 (es) * 1972-06-29 1976-07-07 Ciba Geigy Ag Procedimiento para la obtencion de compuestos de acido 7beta-amino-3-cefem-3-01-4-carboxilico0-substituidos
US3932386A (en) * 1973-06-18 1976-01-13 American Home Products Corporation Sodium 6-(L-aminocyclohexane carboxamido)penicillanic acid
GB1563103A (en) * 1975-10-13 1980-03-19 Beecham Group Ltd Process for the preparation of clavulanic acid
NZ189022A (en) * 1977-12-08 1981-11-19 Beecham Group Ltd Pharmaceutically acceptable particles of clavulanates dispersed in a polymeric binder
US4454069A (en) * 1979-08-24 1984-06-12 Beecham Group Limited Clavulanic acid salts and their preparation from the tertiary butyl amine salt
EP0053893B1 (de) * 1980-12-09 1985-03-20 Beecham Group Plc Clavulansäure-Derivate, ihre Herstellung und ihre Verwendung
US4522701A (en) * 1982-02-11 1985-06-11 E. I. Du Pont De Nemours And Company Process for preparing an anisotropic aromatic pitch
US4456753A (en) * 1983-02-07 1984-06-26 Pfizer Inc. Process for the manufacture of highly crystalline sodium cefoperazone
DE3314725A1 (de) * 1983-04-22 1984-10-25 Siemens AG, 1000 Berlin und 8000 München Oberflaechenwellen-resonatorfilter
US4659812A (en) * 1985-08-20 1987-04-21 Bristol-Myers Company Cephalosporin intermediates
GB8608962D0 (en) * 1986-04-12 1986-05-14 Beecham Group Plc Beta-lactam antibiotics
US5288861A (en) * 1987-01-29 1994-02-22 Beecham Group Plc Potassium clavulanate in rosette form
PT86631B (pt) * 1987-01-29 1992-01-31 Beecham Group Plc Processo para a preparacao de uma nova forma cristalina de clavulanato de potassio
ES2063974T3 (es) 1989-07-10 1995-01-16 Chemferm Vof Una nueva forma estable de cefradina, un proceso para su produccion y compuestos intermedios usados en tal proceso.
GB9009473D0 (en) 1990-04-27 1990-06-20 Beecham Group Plc Pharmaceutical formulation
US5250525A (en) * 1991-02-12 1993-10-05 Pliva Handels Gmbh 4-oxo-azetidine-2-sulfonic acids and their salts, processes for the preparation thereof and their use
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
AT400033B (de) * 1992-03-10 1995-09-25 Biochemie Gmbh Neues verfahren zur isolierung und reinigung von clavulansäure und zur herstellung von pharmakologisch verträglichen salzen derselben
AT401871B (de) † 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
SI9400107A (en) * 1994-03-02 1995-10-31 Lek Tovarna Farmacevtskih New process of the isolation of clavulanic acid and its pharmaceutical salts from fermented broth of streptomyces sp.p 6621 ferm p 2804.
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE4426973C1 (de) * 1994-07-29 1996-03-28 Degussa Verfahren zur Herstellung eines als Brennstoffzellenelektrode einsetzbaren Plattinlegierungskatalysators
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
ZA975198B (en) * 1996-06-13 1997-12-15 Smithkline Beecham Corp Improved process for preparing potassium clavulanate.
EP0912169A2 (de) 1996-07-16 1999-05-06 Gist-Brocades B.V. Organische lösungsmittelfreie beta-lactam enthaltende granulate
GB9616536D0 (en) † 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
CN1238776A (zh) * 1996-11-11 1999-12-15 吉斯特-布罗卡迪斯有限公司 制备棒酸盐和酯的方法
ATE187498T1 (de) * 1997-03-24 1999-12-15 Cipan Comp Ind Prod Verfahren zur isolierung eines pharmazeutisch verträglichen alkalimetallsalzes der clavulansäure
WO1999011261A1 (en) † 1997-08-29 1999-03-11 Dsm N.V. Granules free of excipients

Also Published As

Publication number Publication date
DE60008508T3 (de) 2012-01-19
CA2364342A1 (en) 2000-07-20
AU3817300A (en) 2000-08-01
DE60008508T2 (de) 2004-12-23
EP1165049B2 (de) 2011-07-06
DE60008508D1 (de) 2004-04-01
ES2215628T3 (es) 2004-10-16
EP1165049A2 (de) 2002-01-02
US20060079496A1 (en) 2006-04-13
US6979735B1 (en) 2005-12-27
MXPA01009808A (es) 2002-04-24
US20110045082A1 (en) 2011-02-24
SI1165049T2 (sl) 2011-11-30
ES2215628T5 (es) 2011-11-28
CA2364342C (en) 2011-02-01
DE60008508T9 (de) 2012-06-14
SI1165049T1 (en) 2004-12-31
WO2000041478A3 (en) 2000-11-02
CN1345231A (zh) 2002-04-17
WO2000041478A2 (en) 2000-07-20
CN1209099C (zh) 2005-07-06
EP1165049B1 (de) 2004-02-25
TR200102771T2 (tr) 2002-04-22

Similar Documents

Publication Publication Date Title
ATE260096T1 (de) Agglomerate durch kristallisation
WO2002074767A8 (en) Metalloproteinase inhibitors
DK1537097T3 (da) Fremgangsmåde til fremstilling af 3-Halo-4,5-dihydro-1H-pyrazoler
WO2004078923A3 (en) Pyk2 crystal structure and uses
WO2001017973A3 (de) Neue herbizide
WO2002074752A8 (en) Metalloproteinase inhibitors
WO1997047270A3 (en) Novel anti-viral compounds
EP1577286A4 (de) Perfluorallyloxyverbindung und diese verbindung enthaltende flüssigkristalline zusammensetzung
WO2002083616A1 (fr) DERIVE D'ACIDE GRAS φomega;-ARYLE α-SUBSTITUE
WO2006006040A3 (en) News diamine salts of cephalosporin antibiotics and their preparation
EP1555261A4 (de) Valerolactonverbindungen und parf mzusammensetzung
WO2003029254A1 (fr) Procede de preparation de composes tricycliques
EP1355966B8 (de) Mit aktinischer strahlung aktivierbare blends aus kristallinen und amorphen verbindungen, verfahren zu ihrer herstellung und ihre verwendung
WO2000071553A8 (en) Novel aluminosiloxane compound and process for preparing the same
MA26299A1 (fr) Procede pour la surveillance et le controle des thysanopteres
YU27099A (sh) Postupak i intermedijari za proizvodnju piridin-2,3- dikarboksilat jedinjenja
TR200001819T2 (tr) COPD tedavi yöntemi.
WO1998034584A3 (en) Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
ID27440A (id) Proses untuk menyiapkan penengah-penengah
EE05136B1 (et) Asendatud imidasopridiinhendite valmistamise meetod
CA2366600A1 (en) A process for the preparation of 1,4,7,10-tetraazacyclododecane
SE0101323D0 (sv) New process
ITRM20010309A1 (it) Procedimento per la produzione di composti perfluoro-organici mediante florurazione elettrochimica.
EP1300391A4 (de) Verfahren zur produktion von 3-amino-2-hydroxypropionsäure-derivaten
ATE286497T1 (de) Herstellung von hydroxyverbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165049

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1165049

Country of ref document: EP